H.C. Wainwright Initiated Avenue Therapeutics (ATXI)’s Coverage with $11.0000 Target; Profile of 4 Analysts Covering Cobham plc (LON:COB)

Cobham plc (LON:COB) Logo

Among 20 analysts covering Cobham PLC (LON:COB), 4 have Buy rating, 5 Sell and 11 Hold. Therefore 20% are positive. Cobham PLC had 196 analyst reports since July 29, 2015 according to SRatingsIntel. JP Morgan maintained Cobham plc (LON:COB) on Friday, November 6 with “Overweight” rating. Deutsche Bank upgraded the stock to “Hold” rating in Thursday, April 28 report. The rating was upgraded by Kepler Cheuvreux to “Buy” on Tuesday, August 11. The stock has “Neutral” rating by UBS on Friday, February 26. Citigroup maintained Cobham plc (LON:COB) on Friday, June 15 with “Neutral” rating. The rating was maintained by Liberum Capital on Tuesday, March 28 with “Hold”. Canaccord Genuity maintained Cobham plc (LON:COB) rating on Monday, August 8. Canaccord Genuity has “Hold” rating and GBX 160 target. Deutsche Bank maintained the shares of COB in report on Monday, June 13 with “Hold” rating. The firm earned “Neutral” rating on Thursday, January 12 by Goldman Sachs. The firm has “Sell” rating given on Friday, December 4 by Deutsche Bank. See Cobham plc (LON:COB) latest ratings:

18/06/2018 Broker: Morgan Stanley Rating: Overweight Old Target: GBX 115.00 New Target: GBX 150.00 Upgrade
15/06/2018 Broker: Citigroup Rating: Neutral Old Target: GBX 143.00 New Target: GBX 135.00 Maintain
31/05/2018 Broker: AlphaValue Rating: Add Downgrade
26/04/2018 Broker: Liberum Capital Rating: Hold Old Target: GBX 120.00 New Target: GBX 120.00 Maintain
28/03/2018 Broker: Morgan Stanley Rating: Equal Weight Maintain
16/03/2018 Broker: Deutsche Bank Rating: Sell Maintain
05/03/2018 Broker: Berenberg Rating: Hold Old Target: GBX 130.00 New Target: GBX 134.00 Reiteration
06/03/2018 Broker: Deutsche Bank Rating: Sell Old Target: GBX 110.00 New Target: GBX 115.00 Maintain
05/03/2018 Broker: JP Morgan Rating: Neutral Old Target: GBX 135.00 New Target: GBX 135.00 Maintain
02/03/2018 Broker: Barclays Capital Rating: Equal Weight Old Target: GBX 130.00 New Target: GBX 133.00 Maintain

H.C. Wainwright has started its coverage on Avenue Therapeutics Inc (ATXI), today Monday morning. The broker finds the stock of ATXI attractive and has target of $11.0000 with “Buy” rating.

The stock decreased 1.04% or GBX 1.35 during the last trading session, reaching GBX 128.5. About 696,315 shares traded. Cobham plc (LON:COB) has 0.00% since June 25, 2017 and is . It has underperformed by 12.57% the S&P500.

Cobham plc provides a range of technologies and services to commercial, defense, and security markets in the United Kingdom, the United States, Other European countries, Australia, andinternationally. The company has market cap of 3.06 billion GBP. The firm operates in four divisions: Communications and Connectivity, Mission Systems, Advanced Electronic Solutions, and Aviation Services. It has a 36.71 P/E ratio. The Communications and Connectivity segment offers equipment and solutions for the aerospace, avionics, satellite and radio, wireless, and mobile connectivity markets.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. The company has market cap of $42.42 million. The Company’s product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. It currently has negative earnings.

The stock increased 3.08% or $0.12 during the last trading session, reaching $4.02. About 15,236 shares traded. Avenue Therapeutics, Inc. (ATXI) has 0.00% since June 25, 2017 and is . It has underperformed by 12.57% the S&P500.